On Friday, Following U.S. Stocks were among the “Top Gainers”: Valero Energy Corporation (NYSE:VLO), Depomed Inc (NASDAQ:DEPO), Lam Research Corporation (NASDAQ:LRCX), PDC Energy Inc (NASDAQ:PDCE)
Valero Energy Corporation (NYSE:VLO)’s shares picked up 1.30%, and closed at $58.53. The stock volatility for the week is 2.20%, while for the month remained 2.50%. The company holds consensus target price of $67.57.
If we consider EPS growth of the company, then we will notice the following observations:
The company showed 6.98 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 40.80%, and Annual EPS growth for the past 5 years is considered as 73.40%.
The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).
Valero Energy Corporation operates as an independent petroleum refining and marketing company in the United States, Canada, the Caribbean, the United Kingdom, and Ireland. It operates through two segments, Refining and Ethanol. The Refining segment is involved in refining, wholesale marketing, product supply and distribution, and transportation operations. This segment produces conventional and premium gasolines, gasoline meeting the specifications of the California Air Resources Board (CARB), reformulated gasoline blendstock for oxygenate blending, diesel fuels, low-sulfur and ultra-low-sulfur diesel fuels, CARB diesel fuel, distillates, jet fuels, asphalts, petrochemicals, lubricants, and other refined products. The Ethanol segment produces and sells ethanol and distillers grains.
Depomed Inc (NASDAQ:DEPO), raised 1.29%, and closed at $25.20, hitting new 52-week high of $25.29. The company holds the market capitalization of 1.50B. For the trailing twelve months, the stock’s return on equity value remains 61.90%, while return on assets value is 25.20%, in response to its return on investment value of 25.60%. Its 20-day moving average gained 14.53%, above 50-day moving average of 29.17%, above 200-day moving average of 63.41% from the latest market price of $25.20. The mean recommendation of analysts for this stock is 1.80.(where 1=Buy, 5=Sale).
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies.
Lam Research Corporation (NASDAQ:LRCX), enhanced 1.27%, and closed at $78.71. The stock has price to sale value of 2.58, however, price to book value is 2.51. With recent incline, the year-to-date (YTD) performance reflected a -0.57% decline below last year. During the past month the stocks gain 50.15%, bringing three-month performance to -1.02% and six-month performance to 8.87%. The mean recommendation of analysts for this stock is 1.90. (where 1=Buy, 5=Sale).
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing systems used in the fabrication of integrated circuits. The company provides thin film deposition products, counting SABRE Product Family for copper damascene manufacturing; ALTUS systems deposit conformal atomic layer films for tungsten metallization applications; VECTOR family of plasma-improved chemical vapor deposition systems for the deposition of ashable hardmasks, oxides, nitrides, carbides, and anti-reflective layers; SPEED high-density plasma-chemical vapor deposition products for applications in STI, pre-metal dielectrics, inter-layer dielectrics, inter-metal dielectrics, and passivation layers; and SOLA ultraviolet thermal processing product family for the treatment of back-end-of-line low-k dielectric films and front-end-of-line silicon nitride strained films.
PDC Energy Inc (NASDAQ:PDCE), rose 1.27%, and closed at $51.88. The stock has the beta value of 1.56, and its volatility for the week is 4.45%, while for the month it is 5.21%. The company has the market capitalization of $1.87B. The company holds the book value per share of 31.73, whereas cash per share is 0.45. Price to book value is estimated to be 1.64, while price to sale value is 2.18. Analysts mean recommendation for the stock is said to be 2.00 (where 1=Buy, 5=sale).
PDC Energy, Inc., an independent exploration and production company, attains, explores for, develops, and produces crude oil, natural gas, and natural gas liquids in the United States. The company operates in two segments: Oil and Gas Exploration and Production, and Gas Marketing. The Oil and Gas Exploration and Production segment produces and sells natural gas to midstream service providers, marketers, and utilities; crude oil; and natural gas liquids.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
